Enhancing the efficacy of mesenchymal stem cell therapy.
Enhancing the efficacy of mesenchymal stem cell therapy.
复制标题
DOI：
10.4252/wjsc.v6.i2.82
复制
发表时间：
2014-04-26
影响因子：
4.1
通讯作者：
Lee, Techung
中科院分区：
文献类型：
--
作者：
Mastri, Michalis;Lin, Huey;Lee, Techung
间充质干细胞（MSC）治疗在完成许多临床前和临床试验后正进入一个具有挑战性的阶段。MSC治疗中遇到的主要障碍包括干细胞效力不一致、细胞植入和存活率差以及年龄/疾病相关的宿主组织损伤。MSC主要通过旁分泌机制介导治疗益处而不依赖于细胞分化的认识为增强干细胞效力和治疗益处提供了有希望的框架。几种MSC引发方法被强调，这将可能使我们能够充分利用成体干细胞的潜力，用于其未来的常规临床应用。
Mesenchymal stem cell (MSC) therapy is entering a challenging phase after completion of many preclinical and clinical trials. Among the major hurdles encountered in MSC therapy are inconsistent stem cell potency, poor cell engraftment and survival, and age/disease-related host tissue impairment. The recognition that MSCs primarily mediate therapeutic benefits through paracrine mechanisms independent of cell differentiation provides a promising framework for enhancing stem cell potency and therapeutic benefits. Several MSC priming approaches are highlighted, which will likely allow us to harness the full potential of adult stem cells for their future routine clinical use.